FDA Office of New Drugs (correction)
A chart outlining the new structure of the Office of New Drugs published in the June 27 issue of "The Pink Sheet" incorrectly reported the status of the division directors in the Office of Non-Prescription Products. Curtis Rosebraugh is acting director for the Division of Non-Prescription Clinical Evaluation, and Susan Johnson is acting director for the Division of Non-Prescription Regulation Development. An accompanying story also suggested that Robert Justice is the permanent director of the Division of Drug Oncology Products; he will serve on an acting basis...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.